Zhigang Chang1, Yongqing Li, Wei He, Baoling Liu, Ihab Halaweish, Ted Bambakidis, Yingjian Liang, Hasan B Alam. 1. From the Department of Surgical ICU (Z.C.), Beijing Hospital Ministry of Health, Beijing; Department of Cardiothoracic Surgery (W.H.), Zhongda Hospital, School of Medicine, Southeast University, Nanjing; and The First Hospital (Y.Lia.), China Medical University, Shengyang, China; and Department of Surgery (Z.C., Y.Li., W.H., B.L., I.H., T.B., Y.Lia., H.B.A.), University of Michigan Hospital, Ann Arbor, Michigan.
Abstract
BACKGROUND: Hemorrhage is the leading cause of preventable trauma-related deaths. We have previously shown that treatment with Tubastatin A (Tub A), a histone deacetylase 6 (HDAC6) inhibitor, can improve survival in a rodent model of septic shock. The aims of the present study were to determine whether selective inhibition of HDAC6 can promote survival in a model of hemorrhagic shock (HS). METHODS: In Experiment I (survival study), Wistar-Kyoto rats were subjected to HS (55% volume blood loss), followed by intraperitoneal injection of either Tub A (70 mg/kg) dissolved in dimethyl sulfoxide (DMSO) or DMSO only (vehicle group) (n = 8 per group). Survival was monitored for 24 hours. In Experiment II (physiologic study), rats were subjected to a sublethal HS (40% blood loss), followed by the same treatment with Tub A (treatment group) or DMSO only (vehicle group, n = 5 per group). All animals were sacrificed 6 hours after hemorrhage, and the heart and liver tissues were harvested. Sham animals were not subjected to hemorrhage and treatment (sham group, n = 5 per group). Cardiac mitochondria were isolated to study the pyruvate dehydrogenase (PDH, an essential enzyme for adenosine triphosphate production) activity. Liver tissue lysates were analyzed for markers of apoptosis (cytochrome c, cleaved caspase 3) and inflammation (high-mobility group box 1) by Western blotting. RESULTS: Severe HS (55% blood loss) was associated with 75% mortality, which was significantly improved by Tub A treatment (37.5% mortality in 24 hours, p = 0.048). Tub A also significantly enhanced the cardiac PDH activity compared with the vehicle group, while suppressing the hepatic high-mobility group box 1 expression, cytochrome c release, and caspase 3 activation. CONCLUSION: Our study has demonstrated for the first time that selective inhibition of HDAC6 can improve survival in a rodent model of HS. The potential mechanisms include enhanced PDH activity, decreased inflammatory drive, and attenuated cellular apoptosis.
BACKGROUND:Hemorrhage is the leading cause of preventable trauma-related deaths. We have previously shown that treatment with Tubastatin A (Tub A), a histone deacetylase 6 (HDAC6) inhibitor, can improve survival in a rodent model of septic shock. The aims of the present study were to determine whether selective inhibition of HDAC6 can promote survival in a model of hemorrhagic shock (HS). METHODS: In Experiment I (survival study), Wistar-Kyoto rats were subjected to HS (55% volume blood loss), followed by intraperitoneal injection of either Tub A (70 mg/kg) dissolved in dimethyl sulfoxide (DMSO) or DMSO only (vehicle group) (n = 8 per group). Survival was monitored for 24 hours. In Experiment II (physiologic study), rats were subjected to a sublethal HS (40% blood loss), followed by the same treatment with Tub A (treatment group) or DMSO only (vehicle group, n = 5 per group). All animals were sacrificed 6 hours after hemorrhage, and the heart and liver tissues were harvested. Sham animals were not subjected to hemorrhage and treatment (sham group, n = 5 per group). Cardiac mitochondria were isolated to study the pyruvate dehydrogenase (PDH, an essential enzyme for adenosine triphosphate production) activity. Liver tissue lysates were analyzed for markers of apoptosis (cytochrome c, cleaved caspase 3) and inflammation (high-mobility group box 1) by Western blotting. RESULTS: Severe HS (55% blood loss) was associated with 75% mortality, which was significantly improved by Tub A treatment (37.5% mortality in 24 hours, p = 0.048). Tub A also significantly enhanced the cardiac PDH activity compared with the vehicle group, while suppressing the hepatic high-mobility group box 1 expression, cytochrome c release, and caspase 3 activation. CONCLUSION: Our study has demonstrated for the first time that selective inhibition of HDAC6 can improve survival in a rodent model of HS. The potential mechanisms include enhanced PDH activity, decreased inflammatory drive, and attenuated cellular apoptosis.
Authors: Jim P Dompierre; Juliette D Godin; Bénédicte C Charrin; Fabrice P Cordelières; Stephen J King; Sandrine Humbert; Frédéric Saudou Journal: J Neurosci Date: 2007-03-28 Impact factor: 6.167
Authors: Mark A Rivieccio; Camille Brochier; Dianna E Willis; Breset A Walker; Melissa A D'Annibale; Kathryn McLaughlin; Ambreena Siddiq; Alan P Kozikowski; Samie R Jaffrey; Jeffery L Twiss; Rajiv R Ratan; Brett Langley Journal: Proc Natl Acad Sci U S A Date: 2009-11-02 Impact factor: 11.205
Authors: Earl Gonzales; Huazhen Chen; Richard Munuve; Tina Mehrani; Joy Britten-Webb; Amal Nadel; Hasan B Alam; David Wherry; David Burris; Elena Koustova Journal: Shock Date: 2006-04 Impact factor: 3.454
Authors: Panpan Chang; Michael Weykamp; Isabel S Dennahy; Aaron M Williams; Umar F Bhatti; Baoling Liu; Vahagn C Nikolian; Yongqing Li; Hasan B Alam Journal: J Trauma Acute Care Surg Date: 2018-05 Impact factor: 3.313
Authors: Aaron M Williams; Isabel S Dennahy; Umar F Bhatti; Ben E Biesterveld; Nathan J Graham; Yongqing Li; Hasan B Alam Journal: Shock Date: 2019-09 Impact factor: 3.454
Authors: Peter J Bruhn; Vahagn C Nikolian; Ihab Halaweish; Zhigang Chang; Martin Sillesen; Baoling Liu; Yongqing Li; Hasan B Alam Journal: J Trauma Acute Care Surg Date: 2018-02 Impact factor: 3.313